Michael Birrer
Hematology & Oncology · Birmingham, ALNPI 1164643714
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $248,882 of the $301,845 with a category attached, or 82.5%. 15 manufacturers reported payments, led by AstraZeneca at 32.6% of the total. Reporting peaked in 2019 at $126,213 and has fallen 89.1% since, to $13,820 in 2025. Among hematology & oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $1089.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$98K
- GSK$43K
- Astrazeneca UK Limited$41K
- Eisai Inc.$31K
- Merck$26K
- Genentech USA, Inc.$17K
- plus $45K from 9 others
Across 126 payments — averaging $6076.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$418K
- Takeda Pharmaceuticals U.S.A., Inc.$125K
- Blueprint Medicines Corporation$100K
- Deciphera Pharmaceuticals Inc.$71K
- Exelixis Inc.$50K
- Sanofi US Services Inc.$1K
What the payments were for
- Consulting fees$248,88282%
- Speaking & faculty fees$22,7308%
- Travel & lodging$23,0948%
- Food & beverage$7,1392%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 85 | $98,324 |
| GSK | 30 | $43,250 |
| Astrazeneca UK Limited | 17 | $41,339 |
| Eisai Inc. | 45 | $30,704 |
| Merck | 18 | $25,979 |
| Genentech USA, Inc. | 11 | $17,071 |
| Tesaro, Inc. | 26 | $16,014 |
| EMD Serono, Inc. | 6 | $9,194 |
| Clovis Oncology, Inc. | 24 | $7,258 |
| Aadi Bioscience, Inc. | 5 | $6,206 |
| EMD Serono Research & Development Institute, Inc. | 2 | $3,195 |
| Blueprint Medicines Corporation | 1 | $1,680 |
| Exelixis Inc. | 4 | $948 |
| Pfizer | 2 | $565 |
| Array Biopharma Inc | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$301,845 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
- Christos VaklavasBirmingham$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.